Dyne Therapeutics had its Relative Strength (RS) Rating upgraded from 85 to 92 Thursday.
IBD's unique rating identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of over 80 at the beginning of a new run.
Here Are 3 Keys For Successful Stock Investing
Dyne Therapeutics is now considered extended and out of buy range after clearing a 30.27 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company showed 0% earnings growth last quarter, while sales growth came in at 0%.
The company holds the No. 154 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
